Platform Session 3: Cancer Genetics and Therapeutics
20 Mar 2025
Venue:
Los Angeles Convention Centre
Meeting Room:
502 AB
Cancer Genetics and Therapeutics
-
Accredited:
- Accredited
Platform presentations are abstract submissions chosen by the abstract review committee to orally present their research. It is a 13-minute presentation followed by a 2-minute Q&A.
O06 - Evaluation of Somatic Genetic Testing As a Screening Tool to Detect Hereditary Cancer Predisposition in Patients Diagnosed With Myeloid Malignancies
O07 - Global Collaboration in Childhood Cancer Gene Curation: Formation of the ClinGen Childhood, Adolescent, and Young Adult Cancer Predisposition GCEP
O08 - Assessing the Pathogenicity of BRCA1 BRCT Domain Variants of Uncertain Significance (VUS)
O09 - Prevalence of Germline Variants in Cancer Predisposition Genes in Patients with Pediatric Solid Tumors Using Paired Tumor-Normal Exome Sequencing
O10 - Early Detection of BRCA1/2-Associated Cancers through Multi-Modal Cell-free DNA Analysis
O11 - Mutational Spectra of >1000 Pediatric Acute Leukemias and Their Clinical Utility in Prognosis, Risk Stratification, and Precision Medicine Therapeutics
O06 - Evaluation of Somatic Genetic Testing As a Screening Tool to Detect Hereditary Cancer Predisposition in Patients Diagnosed With Myeloid Malignancies
O07 - Global Collaboration in Childhood Cancer Gene Curation: Formation of the ClinGen Childhood, Adolescent, and Young Adult Cancer Predisposition GCEP
O08 - Assessing the Pathogenicity of BRCA1 BRCT Domain Variants of Uncertain Significance (VUS)
O09 - Prevalence of Germline Variants in Cancer Predisposition Genes in Patients with Pediatric Solid Tumors Using Paired Tumor-Normal Exome Sequencing
O10 - Early Detection of BRCA1/2-Associated Cancers through Multi-Modal Cell-free DNA Analysis
O11 - Mutational Spectra of >1000 Pediatric Acute Leukemias and Their Clinical Utility in Prognosis, Risk Stratification, and Precision Medicine Therapeutics
Agenda
-
1:30 PM – 3:00 PM -
1:30 PM – 3:00 PM -
Evaluation of Somatic Genetic Testing As a Screening Tool to Detect Hereditary Cancer Predisposition in Patients Diagnosed With Myeloid Malignancies1:30 PM – 1:45 PM -
Global Collaboration in Childhood Cancer Gene Curation: Formation of the ClinGen Childhood, Adolescent, and Young Adult Cancer Predisposition GCEP1:45 PM – 2:00 PM -
Assessing the Pathogenicity of BRCA1 BRCT Domain Variants of Uncertain Significance (VUS)2:00 PM – 2:15 PM -
Prevalence of Germline Variants in Cancer Predisposition Genes in Patients with Pediatric Solid Tumors Using Paired Tumor-Normal Exome Sequencing2:15 PM – 2:30 PM -
Early Detection of BRCA1/2-Associated Cancers through Multi-Modal Cell-free DNA Analysis2:30 PM – 2:45 PM -
Mutational Spectra of >1000 Pediatric Acute Leukemias and Their Clinical Utility in Prognosis, Risk Stratification, and Precision Medicine Therapeutics2:45 PM – 3:00 PM -
)
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
)
)
)
)
){kind=logo}
){kind=logo}
){kind=logo}